Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting

Prostate Cancer and Prostatic Diseases volume 9, pages 270–274 (2006)Cite this article

Abstract

Introduction: Multidisciplinary team (MDT) meetings use precise prognostic factors to select treatment options for patients with prostate cancer. Comorbidity is judged subjectively. Recent publications favour the Charlson comorbidity score (CS) for the use in the management of prostate cancer. We assess the feasibility of using the CS by our MDT in planning the treatment of patients with prostate cancer.

Patients and methods: Patients from the histopathology database aged less than 75 years and with a diagnosis of localized prostate cancer between 1993 and 1995 were included in a notes audit. A second group consisted of patients recommended for curative treatment for localized prostate cancer by the local MDT in 2004. Data on comorbidity, prostatic malignancy and survival up to 10 years was collected. The prognostic accuracy of the CS was assessed for those patients offered radical treatment between 1993 and 1995.

Results: Of 1043 patients initially assessed, 37 patients with localized prostate cancer were identified. Using Cox regression, we found the CS to be a statistically significant predictor of survival, following radical treatment for localized prostate cancer (P=0.005). Current practice in 2004 (56 patients) shows a mean (range) Charlson probability of 10-year survival for radical prostatectomy of 0.823 (0.592–0.923) and for radical radiotherapy of 0.653 (0.07–0.936).

Conclusions: Our results support the findings of recent research. We also found the CS easy to calculate and therefore feasible to use in our MDT setting. We propose the introduction of the Charlson score by prostate cancer MDTs to assess age and comorbidity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. The NHS Cancer Plan. DoH: London, 2000.

  2. Wilson J, Clarke M, Ewings P, Graham J, MacDonagh R . The assessment of patient life-expectancy: how accurate are oncologists and urologists? BJU Int 2005; 95: 794–798.

    Article  Google Scholar 

  3. Report from the working party on co-morbidity assessment in cancer – its role in the national core cancer dataset. www.nhsia.nhs.uk,04 Jul 2001.

  4. Singh R, O'Brien TS . Comorbidity assessment in localized prostate cancer: a review of currently available techniques. Eur Urol 2004; 46: 28–41.

    Article  Google Scholar 

  5. Froehner M, Koch R, Litz R, Oehlschlaeger S, Wirth MP . Which conditions contributing to the Charlson score predict survival after radical prostatectomy? J Urol 2004; 171 (Part 1): 697–699.

    Article  Google Scholar 

  6. Froehner M, Koch R, Litz R, Heller A, Oehlschlaeger S, Wirth MP . Comparison of the American society of anesthesiologists physical status classification with the Charlson score as predictors of survival after radical prostatectomy. Urology 2003; 62: 698–701.

    Article  Google Scholar 

  7. Charlson ME, Pompei P, Ales KL, MacKenzie CR . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373–383.

    Article  CAS  Google Scholar 

  8. Charlson ME, Szatrowski TP, Peterson J, Gold J . Validation of a combined co-morbidity index. J Clin Epidemiol 1994; 47: 1245–1251.

    Article  CAS  Google Scholar 

  9. Tewari A, Johnson CC, Divine G, Crawford ED, Gamito EJ, Demers R et al. Long-term survival probability in men with clinically localized prostate cancer: a case–control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 2004; 171: 1513–1519.

    Article  Google Scholar 

  10. Froehner M, Koch R, Litz R, Oehlschlaeger S, Wirth MP . Which conditions contributing to the Charlson score predict survival after radical prostatectomy? J Urol 2004; 171: 697–699.

    Article  Google Scholar 

  11. Froehner M, Koch R, Litz R, Oehlschlaeger S, Hakenberg OW, Wirth MP . Feasibility and limitations of comorbidity measurement in patients undergoing radical prostatectomy. Eur J Urol 2005; 47: 190–195.

    Article  Google Scholar 

  12. Post PN, Hansen BE, Kil PJ, Janssen-Heijnen ML, Coebergh JW . The independent prognostic value of comorbidity among men aged <75 years with localized prostate cancer: a population based study. BJU Int 2001; 87: 821–826.

    Article  CAS  Google Scholar 

  13. Barry MJ, Albertsen PC, Bagshaw MA, Blute ML, Cox R, Middleton RG et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy or expectant management: a retrospective analysis. Cancer 2001; 911: 2302–2314.

    Article  Google Scholar 

  14. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J . The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 1996; 156: 127–132.

    Article  CAS  Google Scholar 

  15. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M et al. Randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 781–789.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, St Richard's Hospital, Chichester, UK

    C Kastner, J Armitage, A Kimble, J Rawal, P G Carter & S Venn

  2. The Prostate Project, Postgraduate Medical School, University of Surrey, Guildford, UK

    C Kastner

  3. Clinical Effectiveness Unit, Royal College of Surgeons, London, UK

    J Armitage

Authors
  1. C Kastner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Armitage
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Kimble
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Rawal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P G Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Venn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Kastner.

Appendix A. Charlson comorbidity score (adapted for clinical use)

Appendix A. Charlson comorbidity score (adapted for clinical use)

Table A1, Table A2 and Table A3

Table 5 Table a1
Full size table
Table 6 Table a2
Full size table
Table 7 Table a3
Full size table

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kastner, C., Armitage, J., Kimble, A. et al. The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting. Prostate Cancer Prostatic Dis 9, 270–274 (2006). https://doi.org/10.1038/sj.pcan.4500889

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500889

Keywords

This article is cited by

Search

Advanced search

Quick links